InvestorsHub Logo
Followers 21
Posts 2723
Boards Moderated 0
Alias Born 01/27/2022

Re: lizzy241 post# 381542

Wednesday, 06/29/2022 1:43:41 PM

Wednesday, June 29, 2022 1:43:41 PM

Post# of 427302
I still think there is the possibility that they contract with HLS to sell V in the U.S., and have Pfizer market to PCP's, as they currently are in Canada. This would be a win-win. And it may open the window to an acquisition. Not unlike what Pfizer did with Lipitor back before they bought Warner-Lambert.

----------------------------

“Pfizer appears to be a very attractive choice for a comarketing partner,” Atkinson said. “It owns and markets the largest branded statin drug on the market (Lipitor, now off patent), has national reach and a strong reputation, and Vascepa is labeled to be taken in conjunction with a statin. Vascepa should be a natural drug for Pfizer reps to discuss with family physicians, as Vascepa can be a method for those reps to also promote Lipitor.”

The agreement will see at least 60 Pfizer representatives marketing Vascepa to between 6,000 and 10,000 family doctors in Canada (out of approximately 45,000), who are responsible for between 70 and 80 per cent of CV script volume within its target cohort, while HLS will continue to leverage its its in-house salesforce of roughly 30 people to market Vascepa to over 2,500 cardiologists and other specialists across Canada."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News